Permits prescription labels for mifepristone, misoprostol, and their generic alternatives to include the name of the prescribing health care practice instead of the name of the prescriber at the prescriber's request.
Summary
S00036 amends New York education law to allow prescription labels for mifepristone, misoprostol, and their generic alternatives to list the name of the dispensing or prescribing health care practice, rather than the individual dispenser or prescriber, in specified circumstances. For dispensing, the label may include the name of the dispensing health care practice instead of the dispenser’s name. For prescribing, the label may include the name of the prescribing health care practice instead of the prescriber’s name, but only at the prescriber’s request.
The bill is narrowly targeted to abortion-related medications and is intended to give clinics and medical practices more flexibility in how these prescriptions are labeled. It takes effect immediately upon enactment and would modify existing labeling requirements in the Education Law for pharmacies and prescribers handling these drugs and their generic equivalents.
Impact
The bill would create a specific exception to New York’s prescription-labeling rules in Education Law sections 6807 and 6810. Instead of requiring the individual dispenser or prescriber’s name on the label, the law would permit the name of the health care practice to appear for mifepristone, misoprostol, and generic alternatives, under the conditions stated in the bill. This change affects pharmacies, prescribers, and health care practices that dispense or prescribe these medications, and it may reduce the visibility of individual clinician names on labels for these drugs.
Sentiment
The bill appears to have received majority support in both chambers, passing the Senate 39-20 and the Assembly 95-42, though not without significant opposition. The vote margins suggest the measure was generally favored by Democratic majorities and opposed by a substantial bloc of Republicans and some others. No committee transcript was provided, so the recorded votes are the main indicator of sentiment.
Contention
The central point of contention is the bill’s connection to mifepristone and misoprostol, medications commonly associated with abortion care. Supporters likely view the measure as a privacy and operational flexibility provision for patients and providers, while opponents may see it as reducing transparency or as facilitating abortion access. The split votes indicate disagreement over both the policy’s practical effect on labeling and its broader implications in the abortion debate.
Same As
Permits prescription labels for mifepristone, misoprostol, and their generic alternatives to include the name of the prescribing health care practice instead of the name of the prescriber at the prescriber's request.
Permits prescription labels for mifepristone, misoprostol, and their generic alternatives to include the name of the prescribing health care practice instead of the name of the prescriber at the prescriber's request.
An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives
Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.
Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Providing for the use of the name of the prescriber's health care practice instead of the name of the prescriber on the prescription label for certain pharmaceuticals.
Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.